公开(公告)号：US4618696A

公开(公告)日：1986-10-21

申请号：US636058

申请日：1984-07-31

Applicant: Gary F. Cooper ,  John A. Edwards ,  Albert R. Van Horn

Inventor： Gary F. Cooper ,  John A. Edwards ,  Albert R. Van Horn

IPC: A61K31/557 ,  A61K31/5575 ,  A61P43/00 ,  C07C67/00 ,  C07C401/00 ,  C07C405/00 ,  C07C177/00

CPC classification number: C07C405/00

Abstract: This invention covers a compound of the formula ##STR1## wherein R is hydrogen, lower alkyl or a pharmaceutically acceptable, non-toxic salt of a compound wherein R is hydrogen; and X is hydrogen, halo, trifluoromethyl, lower alkyl or lower alkoxy; and the wavy lines represent the .alpha. or .beta. configuration with the proviso that when one wavy line is .alpha. the other is .beta..

Abstract translation: 本发明涵盖下式的化合物，其中R是氢，其中R是氢的化合物的低级烷基或药学上可接受的无毒盐; X为氢，卤素，三氟甲基，低级烷基或低级烷氧基; 波浪线表示α或β配置，条件是当一条波浪线为α时，另一条波长为β。

公开(公告)号：US4912235A

公开(公告)日：1990-03-27

申请号：US203398

申请日：1988-06-07

Applicant: Gary F. Cooper ,  Douglas L. Wren ,  Albert R. Van Horn ,  Tsung-Tee Li ,  Colin C. Beard

Inventor： Gary F. Cooper ,  Douglas L. Wren ,  Albert R. Van Horn ,  Tsung-Tee Li ,  Colin C. Beard

IPC: C07C405/00 ,  C07F7/18 ,  C07D315/00 ,  C07C177/00

CPC classification number: C07C405/0016 ,  C07C405/00 ,  C07C405/0025 ,  C07C405/0033 ,  C07C405/0041 ,  C07F7/1856

Abstract: This invention relates to a process for making a compound of formula I ##STR1## in the form of a stereoisomer or mixture thereof, wherein R is hydrogen, lower alkyl; X is hydrogen, halo, trifluoromethyl, lower alkyl or lower alkoxy, and the wavy lines represent the .alpha. or .beta. configuration with the proviso that when one wavy line is .alpha. the other is .beta., or a pharmaceutically acceptable, non-toxic salt of the compound wherein R is hydrogen; novel intermediates useful for preparing these compounds; processes for making the intermediates; and a stereoisomer of the compound of formula I wherein R is methyl and X is hydrogen and a process for making same.

Abstract translation: 本发明涉及以其立体异构体或其混合物的形式制备式I化合物（I）的方法，其中R是氢，低级烷基; X是氢，卤素，三氟甲基，低级烷基或低级烷氧基，波浪线代表α或β构型，条件是当一个波浪线是α时，另一个是β，或药学上可接受的无毒的盐 其中R是氢的化合物; 用于制备这些化合物的新型中间体; 制造中间体的方法; 和其中R是甲基且X是氢的式I化合物的立体异构体及其制备方法。

公开(公告)号：US4780562A

公开(公告)日：1988-10-25

申请号：US776063

申请日：1985-09-13

Applicant: Gary F. Cooper ,  Douglas L. Wren ,  Albert R. Van Horn ,  Tsung-Tee Li ,  Colin C. Beard

Inventor： Gary F. Cooper ,  Douglas L. Wren ,  Albert R. Van Horn ,  Tsung-Tee Li ,  Colin C. Beard

IPC: C07C405/00 ,  C07C17/00

CPC classification number: C07C405/00 ,  C07C405/0016 ,  C07C405/0025 ,  C07C405/0033 ,  C07C405/0041

Abstract: This invention relates to a process for making a compound of formula I ##STR1## in the form of a stereoisomer or mixture thereof, wherein R is hydrogen, lower alkyl; X is hydrogen, halo, trifluoromethyl, lower alkyl or lower alkoxy, and the wavy lines represent the .alpha. or .beta. configuration with the proviso that when one wavy line is .alpha. the other is .beta., or a pharmaceutically acceptable, non-toxic salt of the compound wherein R is hydrogen; novel intermediates useful for preparing these compounds; processes for making the intermediates; and a stereoisomer of the compound of formula I wherein R is methyl and X is hydrogen and a process for making same.

Abstract translation: 本发明涉及以其立体异构体或其混合物的形式制备式I化合物（I）的方法，其中R是氢，低级烷基; X是氢，卤素，三氟甲基，低级烷基或低级烷氧基，波浪线代表α或β构型，条件是当一个波浪线是α时，另一个是β，或药学上可接受的无毒的盐 其中R是氢的化合物; 用于制备这些化合物的新型中间体; 制造中间体的方法; 和其中R是甲基且X是氢的式I化合物的立体异构体及其制备方法。

公开(公告)号：US4804787A

公开(公告)日：1989-02-14

申请号：US785934

申请日：1985-10-09

Applicant: Gary F. Cooper ,  Douglas L. Wren ,  Albert R. Van Horn ,  Tsung-Tee Li ,  Colin C. Beard

Inventor： Gary F. Cooper ,  Douglas L. Wren ,  Albert R. Van Horn ,  Tsung-Tee Li ,  Colin C. Beard

IPC: C07C405/00 ,  C07F7/18 ,  C07C41/00

CPC classification number: C07C405/00 ,  C07C405/0016 ,  C07C405/0025 ,  C07C405/0041 ,  C07F7/1856

Abstract: This invention relates to a process for making an enantiomer or racemic mixture of a compound of the formula ##STR1## wherein R is hydrogen, lower alkyl or a pharmaceutically acceptable, non-toxic salt of a compound wherein R is hydrogen; X is hydrogen, halo, trifluoromethyl, lower alkyl or lower alkoxy, and the wavy lines represent the .alpha. or .beta. configuration with the proviso that when one wavy line is .alpha. the other is .beta.; novel intermediates useful for preparing these compounds; and processes for making the intermediates.

Abstract translation: 本发明涉及制备下式化合物的对映异构体或外消旋混合物的方法，其中R是氢，其中R是氢的化合物的低级烷基或药学上可接受的无毒盐; X是氢，卤素，三氟甲基，低级烷基或低级烷氧基，波浪线表示α或β构型，条件是当一个波浪线是α时，另一个是β。 用于制备这些化合物的新型中间体; 和制备中间体的方法。

公开(公告)号：US4600785A

公开(公告)日：1986-07-15

申请号：US564386

申请日：1983-12-22

Applicant: Gary F. Cooper ,  Douglas L. Wren ,  Albert R. Van Horn ,  Tsung-Tee Li ,  Colin C. Beard

Inventor： Gary F. Cooper ,  Douglas L. Wren ,  Albert R. Van Horn ,  Tsung-Tee Li ,  Colin C. Beard

IPC: C07B57/00 ,  A61K31/557 ,  A61K31/5575 ,  A61P1/04 ,  C07B31/00 ,  C07B55/00 ,  C07C5/00 ,  C07C67/00 ,  C07C401/00 ,  C07C405/00 ,  C07D309/36 ,  C07F7/08 ,  C07F7/18 ,  C07C177/00

CPC classification number: C07F7/1856 ,  C07C405/00 ,  C07C405/0016 ,  C07C405/0025 ,  C07C405/0041

Abstract: This invention relates to a process for making an enantiomer or racemic mixture of a compound of the formula ##STR1## wherein R is hydrogen, lower alkyl or a pharmaceutically acceptable, non-toxic salt of a compound wherein R is hydrogen; X is hydrogen, halo, trifluoromethyl, lower alkyl or lower alkoxy, and the wavy lines represent the .alpha. or .beta. configuration with the proviso that when one wavy line is a .alpha. the other is .beta.; novel intermediates useful for preparing these compounds; and processes for making the intermediates.

Abstract translation: 本发明涉及制备下式化合物的对映异构体或外消旋混合物的方法，其中R是氢，其中R是氢的化合物的低级烷基或药学上可接受的无毒盐; X是氢，卤素，三氟甲基，低级烷基或低级烷氧基，波浪线表示α或β构型，条件是当一个波浪线是α时，另一个是β; 用于制备这些化合物的新型中间体; 和制备中间体的方法。

公开(公告)号：US4234491A

公开(公告)日：1980-11-18

申请号：US022667

申请日：1979-03-22

Applicant: Gary F. Cooper ,  Albert R. Van Horn

Inventor： Gary F. Cooper ,  Albert R. Van Horn

IPC: C07C51/56 ,  C07D317/26 ,  C07D317/12

CPC classification number: C07D317/26 ,  C07C51/56

Abstract: The tricyclic intermediate ##STR1## is prepared in a three step sequence from the bicyclic intermediate ##STR2## The key step of this process involves the addition of a Grignard reagent to a mixed anhydride. Tricyclic compound of formula (I) may be readily converted by known methods to valuable steroids.

Abstract translation: 三环中间体（I）以三步法从双环中间体（II）制备。该方法的关键步骤包括向混合酸酐中加入格氏试剂。 式（I）的三环化合物可以通过已知方法容易地转化为有价值的类固醇。

公开(公告)号：US4158012A

公开(公告)日：1979-06-12

申请号：US916443

申请日：1978-06-19

Applicant: Gary F. Cooper ,  Albert R. Van Horn

Inventor： Gary F. Cooper ,  Albert R. Van Horn

IPC: C07C69/716 ,  A61K31/585 ,  C07C49/597 ,  C07C49/613 ,  C07C51/56 ,  C07C59/205 ,  C07D317/26 ,  C07J1/00 ,  C07J17/00 ,  C07C61/38

CPC classification number: C07D317/26 ,  C07C51/56

Abstract: The tricyclic intermediate ##STR1## is prepared in a three step sequence from the bicyclic intermediate ##STR2## The key step of this process involves the addition of a Grignard reagent to a mixed anhydride. Tricyclic compound of formula (I) may be readily converted by known methods to valuable steroids.

Abstract translation: {PG，1三环中间体{r1 {tc，1 {tr，29 {rb {rd，dd00335588 {db，b {sd，11 {sb，15 O {A，5 {M，1 {A，2 {LS ，8 {SD，26 {SB，4 O {A，1 {BN，D {SD，5 {SB，15 O {A，2 {BL，8 {BL，B {RD，BFF1 {MR，1 {RD ，335588BBDD / 1 {A，2 {RD，00335588BB {A，4 {BN，0 {A，4 {RD，335588CCCC {A，2 {DB，0 {US，5 {SB， {PS {PS从三环中间体{r1 {tc，1 {tr，28 {rb {rd，033 {a，1 {sd，15 {sb，4 CO {HD 2 { A，3 {BU，00 {RD，DD00335588BB {A，2 {DB，B {SD，11 {SB，14 O {A，5 {BN，0 {A，5 {RD，335588CCCC {A，2 {DB ，0 {US，5 {SB，4 O {A，5 {BU，88 {SD，15 {SB，4 H {RE（II）{PS {PS）该过程的关键步骤涉及添加格氏试剂 与混合酸酐反应。 式（I）的三环化合物可以通过已知方法容易地转化为有价值的类固醇。

公开(公告)号：US5342953A

公开(公告)日：1994-08-30

申请号：US648117

申请日：1991-01-31

Applicant: Gary F. Cooper ,  Keith E. McCarthy

Inventor： Gary F. Cooper ,  Keith E. McCarthy

IPC: A61K31/435 ,  A61K31/4365 ,  A61P7/02 ,  C07D291/04 ,  C07D495/04 ,  C07D241/04

CPC classification number: C07D291/04 ,  C07D495/04

Abstract: Compounds of the formula: ##STR1## wherein: A is oxo or dioxo;R.sup.1, R.sup.2 and R.sup.3 are independently hydrogen or lower alkyl of one to six carbon atoms;R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are independently hydrogen, lower alkyl of one to six carbon atoms, alkoxy, acyl or halo;are advantageously converted to thieno[3,2-c]pyridine derivatives and the pharmaceutically acceptable salts thereof, particularly ticlopidine hydrochloride.

Abstract translation: 下式的化合物：其中：A是氧代或二氧代; R1，R2和R3独立地是氢或1-6个碳原子的低级烷基; R4，R5，R6和R7独立地为氢，1-6个碳原子的低级烷基，烷氧基，酰基或卤素; 有利地转化为噻吩并[3,2-c]吡啶衍生物及其药学上可接受的盐，特别是噻氯匹定盐酸盐。

公开(公告)号：US5130432A

公开(公告)日：1992-07-14

申请号：US633636

申请日：1990-12-21

Applicant: Gary F. Cooper ,  Michael G. Martin

Inventor： Gary F. Cooper ,  Michael G. Martin

IPC: C07D207/08 ,  C07D515/04

CPC classification number: C07D207/08 ,  C07D515/04

Abstract: A process for preparing a cyclic amine of Formula I ##STR1## in which R.sup.1 is phenyl, optionally substituted by 1 to 3 lower alkoxy groups;R.sup.2, R.sup.3 and R.sup.4 are independently hydrogen or lower alkyl; andn is 1 or 2,comprises(1) converting an aminoalcohol of Formula III ##STR2## to a dioxooxathiazolidine of Formula II ##STR3## in which R.sup.2, R.sup.3, R.sup.4 and n are as defined above; and (2) reacting the dioxooxathiazolidine of Formula II with an organometallic nucleophile, R.sup.1 M*, wherein R.sup.1 is as defined above, and hydrolyzing the resulting sulfamate salt.

Abstract translation: 制备式I的环胺的方法（I）其中R 1是苯基，任选被1至3个低级烷氧基取代; R2，R3和R4独立地是氢或低级烷基; 并且n为1或2，包括（1）将式III的氨基醇（III）转化为式II的二氧代氧代噻唑烷（II），其中R 2，R 3，R 4和n如上所定义; 和（2）使式II的二氧代氧杂噻唑烷与有机金属亲核试剂R1M *反应，其中R 1如上定义，并水解所得的氨基磺酸盐。

公开(公告)号：US4929740A

公开(公告)日：1990-05-29

申请号：US217241

申请日：1988-07-11

Applicant: Gary F. Cooper

Inventor： Gary F. Cooper

IPC: C07C405/00 ,  C07F7/18

CPC classification number: C07C405/0025 ,  C07F7/1856

Abstract: Compounds of the formula ##STR1## where R.sup.1 and R.sup.2 are hydrogen or an ether-forming group and X is hydrogen, halo, trifluoromethyl, lower alkyl, or lower akoxy, are useful intermediates for making PGE and PGF derivatives having an allenic function.

Abstract translation: 其中R1和R2是氢或醚形成基团，X是氢，卤素，三氟甲基，低级烷基或低级烷氧基的式“IMAGE”的化合物是制备具有富集功能的PGE和PGF衍生物的有用中间体。